<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774878</url>
  </required_header>
  <id_info>
    <org_study_id>TCD10631</org_study_id>
    <secondary_id>EudraCT Number: 2008-000810-54</secondary_id>
    <nct_id>NCT00774878</nct_id>
  </id_info>
  <brief_title>Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer</brief_title>
  <official_title>Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical activity of AVE1642 in combination with
      fulvestrant and of fulvestrant alone in terms of clinical benefit as the rate of &quot;complete
      response&quot;, &quot;partial response&quot; and &quot;stabilization of the disease&quot;.

      The additional objectives are to evaluate the safety profile of AVE1642 in combination with
      fulvestrant and of fulvestrant alone, to assess the rate of patients without disease
      progression at 6 months and the overall progression-free survival time. An evaluation of the
      pharmacokinetics and pharmacodynamics interactions between AVE1642 and fulvestrant will also
      be performed.

      The biological activity of treatment will be assessed on tumor biopsies, when possible The
      potential immunogenicity of AVE1642 will be studied
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study treatment will be administered until disease progression, unacceptable toxicity or
      patient willingness to discontinue.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to discontinue the AVE1642 development program, not due to any safety or
    efficacy concerns
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit defined as a confirmed complete response (CR) or a confirmed partial response (PR) or a stable disease (SD)lasting at least 24 weeks (6 cycles)</measure>
    <time_frame>6 cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free rate</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (TEAEs, hematology, biochemistry parameters)</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVE1642</intervention_name>
    <description>AVE1642 is administered intravenously at the dose of 8 mg/kg.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women

          -  Aromatase inhibitor as the last hormonal treatment

          -  Breast adenocarcinoma with positive hormone receptor

          -  Measurable disease as per RECIST definition

        Exclusion Criteria:

          -  ECOG performance status (PS) &gt; 2

          -  Prior exposure to fulvestrant or to an anti IGF-1R compound

          -  No evidence of hormonosensitivity

          -  HER 2-neu positive tumor

          -  More than one prior regimen of chemotherapy for metastatic disease

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri ROCHE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud (TOULOUSE - FRANCE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>March 2, 2011</last_update_submitted>
  <last_update_submitted_qc>March 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Anti IGF-1R</keyword>
  <keyword>Hormonosensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

